Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma

Published:2022-06 Issue:3 Volume:20 Page:260-269
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Yin Jianyi^ORCID,Elias Roy^ORCID,Peng Lan,Levonyak Nicholas^ORCID,Asokan Annapoorani^ORCID,Christie Alana,Kubiliun Nisa^ORCID,Brugarolas James,Hammers Hans J.

Funder

Exelixis

Bayer

Merck

Burroughs Wellcome Fund

Pfizer

Novartis

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference48 articles.

1. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

2. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

3. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

4. Checkpoint inhibitor immunotherapy in kidney cancer;Xu;Nat Rev Urol,2020

5. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review;Khoja;Ann Oncol,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The gut microbiome and dietary metabolites in the treatment of renal cell carcinoma;Urologic Oncology: Seminars and Original Investigations;2024-08

2. Changes in the Gastrointestinal Microbiota Induced by Proton Pump Inhibitors—A Review of Findings from Experimental Trials;Microorganisms;2024-05-30

3. Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors;Alimentary Pharmacology & Therapeutics;2024-04-08

4. The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review;Cancers;2024-01-31

5. Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients;ESMO Open;2023-12